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ultidrug resistance (MDR) in tuberculosis (TB) threatens the global management of the disease, which is already a leading cause of infectious mortality worldwide, with an estimated 450,000 MDR-TB cases reported in 2012 (1) . Approximately 10% of MDR-TB cases (those resistant to rifampin and isoniazid) are further defined as extensively drug resistant (XDR)-TB, due to their resistance to second-line drugs, fluoroquinolones and injectable aminoglycosides (2) . Long turnaround times (2 to 4 weeks) for phenotypic drug susceptibility testing (DST) (due to the fastidious nature of the organism) can hamper the appropriate treatment of XDR-TB by delaying access to antibiotic susceptibility data (3). Next-generation sequencing (NGS) can highlight resistance in a timely manner in order to effectively manage treatment and minimize further transmission of resistant strains (4) (5) (6) .
The first Irish XDR-TB strain was isolated in the Irish Mycobacteria Reference Laboratory (IMRL) in 2005 (IEXDR1) (7, 8) . First-line DST was completed within 3 weeks (found to be streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide resistant), second-line DST within 5 weeks (found to be amikacin, clarithromycin, ciprofloxacin, and rifabutin resistant, as well as capreomycin, clofazimine, and prothionamide susceptible), and the remainder within 14 weeks (found to be para-aminosalicylate sodium [PAS] resistant and ethionamide and cycloserine susceptible).
In 2014, NGS was performed to provide further molecular characterization of IEXDR1 (lineage 2 or Beijing strain). Genomic DNA was sequenced using an Illumina MiSeq. Paired-end reads were mapped to the Mycobacterium tuberculosis H37Rv reference genome (accession no. AL123456.3) using the Burrows-Wheeler Aligner (9) . This yielded a mapped-read depth of 196-fold, covering 97.6% of the H37Rv genome. A consensus sequence was called using the SAMtools mpileup command (10) . The IMAGE algorithm was employed to extend contigs and close gaps in the assembly, producing a final draft assembly of 4,340,174 bp, consisting of 109 contigs (11) . Single-nucleotide polymorphism (SNP) analysis was performed using Geneious R7 (version 7.1.5; Biomatters); 1,492 SNPs were detected in the assembled genome with respect to the genome of H37Rv, of which 810 were nonsynonymous (depth of coverage, Ն20-fold [average, 276]; variant frequency, Ն95%).
Nonsynonymous mutations were identified in genes Rv0667/ rpoB (H526Y) and Rv1908c/katG (S315T). There is strong correlation between substitutions in rpoB (H526Y) and katG (S315T) and phenotypic resistance to rifampin and isoniazid, respectively (4, 12) . High-confidence SNPs were also found for fluoroquinolone resistance in gene Rv0006 (gyrA) (D94A) and aminoglycoside resistance in MTB000019/rrs (a1401g) (12) . This is consistent with the XDR phenotype of IEXDR1. Other highconfidence mutations found in IEXDR1 for ethambutol (Rv3795/embB [M306V]) and streptomycin (Rv0682/rpsL [K43R]) correlate with its drug resistance profile (13, 14) . SNPs that may confer resistance to pyrazinamide (Rv2043c/pncA [G132C]) and PAS (Rv3764c/thyA [Q97R]) were also identified, although their specificities and sensitivities are not as well defined (http://www.broadinstitute.org/annotation/genome /mtb_drug_resistance.1/DirectedSequencingHome.html).
Previously (15) .
In summary, using NGS, this isolate was confirmed to be XDR-TB in a considerably shorter turnaround time than that for conventional DST. This underlines the potential of NGS in the diagnostic laboratory, especially for MDR-and XDR-TB cases.
Nucleotide sequence accession number. This whole-genome sequencing project has been deposited in the European Nucleotide Archive under the accession no. CCJS00000000. 
